Sutro Biopharma, Inc. (FRA:S090)
Germany
· Delayed Price · Currency is EUR 6.78
-0.41 (-5.70%)
At close: Dec 2, 2025
Sutro Biopharma Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Net Income | -216.77 | -227.46 | -106.79 | -119.2 | -105.54 | -32.13 | Upgrade
|
| Depreciation & Amortization | 7.57 | 7.22 | 6.82 | 5.69 | 4.84 | 4.3 | Upgrade
|
| Loss (Gain) From Sale of Investments | -4.44 | -41.86 | -18.99 | -16.57 | 7.24 | -41.01 | Upgrade
|
| Stock-Based Compensation | 18.27 | 24.69 | 24.91 | 26.3 | 23.24 | 11.92 | Upgrade
|
| Other Operating Activities | 43.65 | 36.97 | 16.82 | 2.92 | 6.16 | 0.61 | Upgrade
|
| Change in Accounts Receivable | 2.73 | 27.46 | -28.96 | 5.34 | -6.9 | 0.74 | Upgrade
|
| Change in Accounts Payable | 1.08 | 0.71 | 4.81 | -1.23 | 2.71 | -1.14 | Upgrade
|
| Change in Unearned Revenue | -77.82 | 7.85 | -32.6 | 93.65 | -15.21 | -14.96 | Upgrade
|
| Change in Other Net Operating Assets | 3.2 | -27.11 | 22.37 | 6.64 | 1.77 | 3.87 | Upgrade
|
| Operating Cash Flow | -222.53 | -191.54 | -111.62 | 3.55 | -81.68 | -67.8 | Upgrade
|
| Capital Expenditures | -2.58 | -3.1 | -4.32 | -7.86 | -15.32 | -7.13 | Upgrade
|
| Investment in Securities | 116.38 | 221.61 | 0.39 | -27.17 | -82 | 7.64 | Upgrade
|
| Other Investing Activities | - | - | - | 0.01 | 0.01 | 0.09 | Upgrade
|
| Investing Cash Flow | 113.8 | 218.51 | -3.92 | -35.02 | -97.32 | 0.6 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | - | 25 | Upgrade
|
| Total Debt Issued | - | - | - | - | - | 25 | Upgrade
|
| Long-Term Debt Repaid | - | -4.08 | -12.5 | -9.38 | - | -10 | Upgrade
|
| Net Debt Issued (Repaid) | - | -4.08 | -12.5 | -9.38 | - | 15 | Upgrade
|
| Issuance of Common Stock | 0.37 | 98.65 | 14.34 | 58.15 | 4.25 | 254.56 | Upgrade
|
| Repurchase of Common Stock | -0.29 | -0.51 | -0.49 | -0.46 | -0.99 | -0.31 | Upgrade
|
| Other Financing Activities | - | - | 136.21 | - | - | - | Upgrade
|
| Financing Cash Flow | 0.08 | 94.05 | 137.55 | 48.31 | 3.26 | 269.25 | Upgrade
|
| Net Cash Flow | -108.65 | 121.02 | 22.01 | 16.84 | -175.74 | 202.05 | Upgrade
|
| Free Cash Flow | -225.11 | -194.64 | -115.93 | -4.31 | -97 | -74.93 | Upgrade
|
| Free Cash Flow Margin | -213.08% | -313.72% | -75.41% | -6.36% | -156.76% | -175.39% | Upgrade
|
| Free Cash Flow Per Share | -26.87 | -25.33 | -19.27 | -0.85 | -21.03 | -23.00 | Upgrade
|
| Cash Interest Paid | 0.25 | 0.31 | 1.13 | 1.87 | 2.05 | 1.68 | Upgrade
|
| Cash Income Tax Paid | 2.37 | 17.52 | 0.38 | - | 0.1 | - | Upgrade
|
| Levered Free Cash Flow | -143.39 | -79.8 | -36.57 | -41.16 | -59.62 | -38.79 | Upgrade
|
| Unlevered Free Cash Flow | -119.24 | -59.57 | -21.72 | -36.53 | -57.62 | -37.04 | Upgrade
|
| Change in Working Capital | -70.81 | 8.9 | -34.38 | 104.41 | -17.62 | -11.49 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.